Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT00153959 Completed - Schizophrenia Clinical Trials

Psychiatric Day Hospital Treatment

Start date: n/a
Phase: N/A
Study type: Interventional

The aim of the study was to compare the effectiveness of acute psychiatric day care to conventional inpatient care within a cross-national multi-site randomised controlled trial.

NCT ID: NCT00149812 Completed - Depression Clinical Trials

A Clinic-based Prevention Program for Families of Depressed Mothers

Start date: January 2005
Phase: Phase 1
Study type: Interventional

This study will assess the effectiveness of the "Keeping Families Strong" program (KFS) in avoiding or delaying the onset of psychiatric disorders among children with depressed mothers.

NCT ID: NCT00149799 Completed - Anxiety Disorders Clinical Trials

Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder

Start date: May 2005
Phase: Phase 3
Study type: Interventional

This study's primary aim is to compare time to relapse and relapse rates in responders to acute escitalopram who are then randomized to placebo versus continuation treatment with escitalopram.

NCT ID: NCT00149747 Completed - Clinical trials for Sleep Initiation and Maintenance Disorders

The Effectiveness of Regular Exercise on Improving Sleep in Older Adults

RTC
Start date: August 1999
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate the effect of regular aerobic exercise on improving sleep in older adults with moderate difficulty sleeping.

NCT ID: NCT00149669 Completed - Clinical trials for Opioid-Related Disorders

Employment-based Reinforcement of Naltrexone Ingestion and Abstinence

Start date: December 2005
Phase: N/A
Study type: Interventional

A randomized study is planned over 5 years to evaluate the effectiveness of the Therapeutic Workplace in promoting naltrexone ingestion and abstinence in unemployed opiate-dependent injection drug users. Participants will be offered an opioid detoxification and naltrexone induction. Participants who complete the naltrexone induction will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and prescribed naltrexone for 26 weeks. The groups will differ in the contingencies imposed to work and earn salary. Work Plus Naltrexone Contingency participants will be required to ingest naltrexone to work, and will receive a brief pay decrease for missing a dose. Work Plus Naltrexone Prescription participants will be prescribed naltrexone, but will not be required to ingest it to work. This study will provide a rigorous evaluation of a novel employment-based intervention, the Therapeutic Workplace, to promote naltrexone ingestion and drug abstinence in a population of injection drug users who are at considerable risk of spreading or contracting HIV infection. Hypotheses being tested in this study are: Naltrexone ingestion will be maintained in the group exposed to the employment-based naltrexone treatment significantly more than the group exposed to usual-care treatment package. Opiate abstinence will be maintained in the group exposed to the employment-based naltrexone treatment significantly more than the group exposed to usual-care treatment package.

NCT ID: NCT00145847 Completed - Schizophrenia Clinical Trials

Naltrexone Treatment of Alcohol Abuse in Schizophrenia

Start date: April 2003
Phase: Phase 4
Study type: Interventional

The primary purpose of this study is to determine whether naltrexone is effective in the treatment of alcohol dependence and abuse in patients with schizophrenia and schizoaffective disorder. Hypotheses are as follows: hypothesis 1: Naltrexone will be more effective than placebo in reducing alcohol use. hypothesis 2: Patients responding to naltrexone by reducing alcohol use will also show reductions in severity of psychiatric symptoms and utilization of inpatient and emergency psychiatric services. hypothesis 3: Severity of psychiatric symptoms and amount of service utilization will correlate positively with alcohol use.

NCT ID: NCT00145678 Completed - Clinical trials for Alcohol Use Disorder

Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use Disorder

Start date: June 2004
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine the feasibility and effectiveness of a modified form of psychodynamic psychotherapy for persons suffering from co-occurring borderline personality disorder and an alcohol use disorder.

NCT ID: NCT00142961 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

Start date: October 2005
Phase: Phase 2
Study type: Interventional

Attention Deficit Hyperactivity Disorder (ADHD) is common among adolescents seeking treatment for marijuana dependence. The purpose of this study is to determine the use of atomoxetine in treating adolescents who abuse marijuana and have ADHD. In addition, this study will assess whether atomoxetine reduces ADHD symptoms as compared to a placebo. Finally, the study will determine whether atomoxetine improves treatment retention and progress in adolescents with ADHD and marijuana dependence.

NCT ID: NCT00142844 Completed - Alcoholism Clinical Trials

Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1

Start date: September 1999
Phase: Phase 2
Study type: Interventional

Many cocaine dependent individuals are also dependent on alcohol. Such individuals respond poorly to existing treatments and have received little research attention in the past. The purpose of this study is to determine whether the combination of naltrexone and disulfiram is useful in decreasing alcohol use and cravings in people diagnosed with both cocaine and alcohol dependence.

NCT ID: NCT00142818 Completed - Alcoholism Clinical Trials

Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence

Mod-Nal
Start date: February 2006
Phase: Phase 2
Study type: Interventional

Modafinil is a medication that may enhance mood and increase energy in cocaine addicts, which may be useful in preventing cocaine relapse. Naltrexone is a medication that is currently used to treat drug and alcohol addiction. A combination of these two medications may be beneficial in reducing drug and alcohol use in individuals undergoing substance abuse treatment. The purpose of this study is to evaluate the effectiveness of modafinil and naltrexone, alone and in combination, at reducing drug and alcohol use in individuals addicted to cocaine and alcohol.